Skip to main content
Top
Published in: Clinical Rheumatology 3/2006

01-05-2006 | Case Report

Transient global amnesia in a patient with high and persistent levels of antiphospholipid antibodies

Authors: Norberto Ortego-Centeno, José Luis Callejas-Rubio, Miguel Guerrero Fernández, Miguel Gómez Camello

Published in: Clinical Rheumatology | Issue 3/2006

Login to get access

Abstract

Cerebrovascular disease is one of the most common symptoms associated with anticardiolipin antibodies (ACA) and lupus anticoagulant (LA), usually in the form of ischemic stroke. However, many other neurologic disorders have been described in patients with antiphospholipid syndrome or ACA. So far, the precise relation between the presence of antibodies and the development of the disease in many of these cases remain unknown. Transient global amnesia (TGA) is an infrequent neurologic disturbance whose precise pathophysiology is not known. It is characterized by a sudden inability to acquire new information, usually lasting no more than 12 h, and it is not accompanied by any other focal neurological signs or symptoms. We report a patient with TGA with persistent and high levels of ACA and LA and suggest that in patients with TGA, investigation of the possible presence of ACA and/or LA may be warranted because a higher prevalence of TGA in the patients with antiphospholipidic syndrome with respect to the general population may lead to further insights into pathogenesis of neurologic disease associated with antiphospholipidic antibodies.
Literature
1.
go back to reference Pantoni L, Lamassa M, Inzitari D (2000) Transient global amnesia: a review emphasizing pathogenic aspects. Acta Neurol Scand 102:275–283CrossRefPubMed Pantoni L, Lamassa M, Inzitari D (2000) Transient global amnesia: a review emphasizing pathogenic aspects. Acta Neurol Scand 102:275–283CrossRefPubMed
2.
go back to reference Hughes GRV (1983) Thrombosis, abortion, cerebral disease and the lupus anticoagulant. Br Med J 287:1088–1089CrossRef Hughes GRV (1983) Thrombosis, abortion, cerebral disease and the lupus anticoagulant. Br Med J 287:1088–1089CrossRef
3.
go back to reference Wilson WA, Gharavi AE, Koike T, Lockshin MD, Branch DW, Piette JC, Brey R, Derksen R, Harris EN, Hughes GR, Triplett DA, Khamashta MA (1999) International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop. Arthritis Rheum 42:1309–1311CrossRefPubMed Wilson WA, Gharavi AE, Koike T, Lockshin MD, Branch DW, Piette JC, Brey R, Derksen R, Harris EN, Hughes GR, Triplett DA, Khamashta MA (1999) International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop. Arthritis Rheum 42:1309–1311CrossRefPubMed
4.
go back to reference Olesen J, Jorgensen MB (1986) Leao's spreading depression in the hippocampus explains transient global amnesia. A hypothesis. Acta Neurol Scand 73:219–220PubMedCrossRef Olesen J, Jorgensen MB (1986) Leao's spreading depression in the hippocampus explains transient global amnesia. A hypothesis. Acta Neurol Scand 73:219–220PubMedCrossRef
5.
go back to reference Rowan AJ, Protass LM (1979) Transient global amnesia: clinical and electroencephalographic findings in 10 cases. Neurology 29:869–872PubMed Rowan AJ, Protass LM (1979) Transient global amnesia: clinical and electroencephalographic findings in 10 cases. Neurology 29:869–872PubMed
6.
7.
go back to reference Zorzon M, Antonutti L, Mase G, Biasutti E, Vitrani B, Cazzato G (1995) Transient global amnesia and transient ischemic attack. Natural history, vascular risk factors, and associated conditions. Stroke 26:1536–1542PubMed Zorzon M, Antonutti L, Mase G, Biasutti E, Vitrani B, Cazzato G (1995) Transient global amnesia and transient ischemic attack. Natural history, vascular risk factors, and associated conditions. Stroke 26:1536–1542PubMed
8.
go back to reference Montalban J, Arboix A, Staub H, Barquinero J, Marti-Vilalta J, Codina A, Hughes GR (1989) Transient global amnesia and antiphospholipid antibodies. Clin Exp Rheumatol 7:85–87PubMed Montalban J, Arboix A, Staub H, Barquinero J, Marti-Vilalta J, Codina A, Hughes GR (1989) Transient global amnesia and antiphospholipid antibodies. Clin Exp Rheumatol 7:85–87PubMed
9.
go back to reference Cervera R, Piette JC, Font J, Khamashta MA, Shoenfeld Y, Camps MT, Jacobsen S, Lakos G, Tincani A, Kontopoulou-Griva I, Galeazzi M, Meroni PL, Derksen RH, de Groot PG, Gromnica-Ihle E, Baleva M, Mosca M, Bombardieri S, Houssiau F, Gris JC, Quere I, Hachulla E, Vasconcelos C, Roch B, Fernandez-Nebro A, Boffa MC, Hughes GR, Ingelmo M, Euro-Phospholipid Project Group (2002) Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients. Arthritis Rheum 46:1019–1027CrossRefPubMed Cervera R, Piette JC, Font J, Khamashta MA, Shoenfeld Y, Camps MT, Jacobsen S, Lakos G, Tincani A, Kontopoulou-Griva I, Galeazzi M, Meroni PL, Derksen RH, de Groot PG, Gromnica-Ihle E, Baleva M, Mosca M, Bombardieri S, Houssiau F, Gris JC, Quere I, Hachulla E, Vasconcelos C, Roch B, Fernandez-Nebro A, Boffa MC, Hughes GR, Ingelmo M, Euro-Phospholipid Project Group (2002) Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients. Arthritis Rheum 46:1019–1027CrossRefPubMed
10.
go back to reference Pantoni L, Lamassa M, Inzitari D (2000) Transient global amnesia: a review emphasizing pathogenic aspects. Acta Neurol Scand 102:275–283CrossRefPubMed Pantoni L, Lamassa M, Inzitari D (2000) Transient global amnesia: a review emphasizing pathogenic aspects. Acta Neurol Scand 102:275–283CrossRefPubMed
11.
go back to reference Melo TP, Ferro JM, Ferro H (1992) Transient global amnesia. A case control study. Brain 115:261–270PubMedCrossRef Melo TP, Ferro JM, Ferro H (1992) Transient global amnesia. A case control study. Brain 115:261–270PubMedCrossRef
12.
go back to reference Jia J, Wang L, Yin L, Tang H (2002) Contrast study on cognitive function with MRI and positron emission tomography imaging in transient global amnesia. Chin Med J (Engl) 115(9):1321–1323 Jia J, Wang L, Yin L, Tang H (2002) Contrast study on cognitive function with MRI and positron emission tomography imaging in transient global amnesia. Chin Med J (Engl) 115(9):1321–1323
13.
go back to reference Leao AAP (1944) Spreading depression of activity in the cerebral cortex. J Neurophysiol 7:359–390 Leao AAP (1944) Spreading depression of activity in the cerebral cortex. J Neurophysiol 7:359–390
14.
go back to reference Sanchez-del-Rio M, Reuter U (2004) Migraine aura: new information on underlying mechanisms. Curr Opin Neurol 17:289–293CrossRefPubMed Sanchez-del-Rio M, Reuter U (2004) Migraine aura: new information on underlying mechanisms. Curr Opin Neurol 17:289–293CrossRefPubMed
15.
go back to reference Hughes GR, Harris NN, Gharavi AE (1986) The anticardiolipin syndrome. J Rheumatol 13:486–489PubMed Hughes GR, Harris NN, Gharavi AE (1986) The anticardiolipin syndrome. J Rheumatol 13:486–489PubMed
16.
go back to reference Shoenfeld Y, Nahum A, Korczyn AD, Dano M, Rabinowitz R, Beilin O, Pick CG, Leider-Trejo L, Kalashnikova L, Blank M, Chapman J (2003) Neuronal-binding antibodies from patients with antiphospholipid syndrome induce cognitive deficits following intrathecal passive transfer. Lupus 12:436–442CrossRefPubMed Shoenfeld Y, Nahum A, Korczyn AD, Dano M, Rabinowitz R, Beilin O, Pick CG, Leider-Trejo L, Kalashnikova L, Blank M, Chapman J (2003) Neuronal-binding antibodies from patients with antiphospholipid syndrome induce cognitive deficits following intrathecal passive transfer. Lupus 12:436–442CrossRefPubMed
Metadata
Title
Transient global amnesia in a patient with high and persistent levels of antiphospholipid antibodies
Authors
Norberto Ortego-Centeno
José Luis Callejas-Rubio
Miguel Guerrero Fernández
Miguel Gómez Camello
Publication date
01-05-2006
Publisher
Springer-Verlag
Published in
Clinical Rheumatology / Issue 3/2006
Print ISSN: 0770-3198
Electronic ISSN: 1434-9949
DOI
https://doi.org/10.1007/s10067-005-0012-5

Other articles of this Issue 3/2006

Clinical Rheumatology 3/2006 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine